UroGen Pharma reported strong third-quarter results, with a notable increase in ZUSDURI's preliminary demand, setting the stage for future growth in an estimated $5 billion market.

• October's preliminary demand revenue for ZUSDURI more than doubled compared to the previous three months, indicating a solid uptick in adoption.
• JELMYTO achieved $25.7 million in net product revenue, a 13% increase year-over-year, illustrating sustained market confidence.
• The positive clinical performance of ZUSDURI, with an 80% complete response rate at three months, positions it as a likely standard of care for bladder cancer.
• UroGen is on track to submit a New Drug Application (NDA) for UGN-103 in the second half of 2026, with FDA approval anticipated in 2027.
• Anticipation of a permanent product-specific J-code for ZUSDURI effective January 1, 2026, could accelerate adoption and reimbursement processes.